UnknownPhase 3NCT02705651
Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment
Studying Functioning neuroendocrine tumor of pancreas
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medical University of Vienna
- Principal Investigator
- Andreas Selberherr, M.D.Medical University of Vienna
- Intervention
- Somatostatin-Analog(drug)
- Enrollment
- 180 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2024
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02705651 on ClinicalTrials.govOther trials for Functioning neuroendocrine tumor of pancreas
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT04919226Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEITM Solucin GmbH
- ACTIVE NOT RECRUITINGPHASE3NCT03375320Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid TumorsNational Cancer Institute (NCI)
- RECRUITINGNCT00830557Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersMayo Clinic
See all trials for Functioning neuroendocrine tumor of pancreas →